Hayley Virgil

The phase 3 ARASENS trial, which assessed the use of darolutamide and docetaxel in patients with metastatic hormone-sensitive prostate cancer, met its primary end point of significantly improved overall survival.

Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IIB or IIC melanoma.

The National Comprehensive Cancer Network has reversed its previous ruling in September and instead recommends patients with low-risk prostate cancer receive active surveillance.

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Panobinostat, which received accelerated approval by the FDA in February 2015 for patients with previously treated multiple myeloma, has had its indication withdrawn in the United States.

A combination of daratumumab, hyaluronidase-fihj, carfilzomib, and dexamethasone has been approved by the FDA for the treatment of relapsed/refractory multiple myeloma.

Imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.

Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.

As the year 2021 comes to a close, CancerNetwork® reviews ongoing clinical research and upcoming innovations in the non–small cell lung cancer space.

Investigators identified an association between the early expansion of Medicaid and a reduction in cancer-related mortality.

Aparna Parikh, MD, MS, discusses how her early experiences with physical fitness shaped her current relationship with exercise.

For Pancretic Cancer Awareness month, CancerNetwork® spoke with Manuel Hidalgo Medina, MD, PhD, about the importance of the phase 2 COMBAT/KEYNOTE-202 trial examining motixafortide and pembrolizumab plus nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic ductal adenocarcinoma.

Patients with advanced renal cell carcinoma who received first-line nivolumab and ipilimumab experienced an improved treatment-free survival vs sunitinib.

Patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin may benefit from treatment with CG0070 plus pembrolizumab.

Investigators announced positive topline results for the phase 3 QuANTUM-First trial, assessing the use of quizartinib plus chemotherapy for adult patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

For patients with HER2-positive metastatic breast cancer, CD8-positive, cytotoxic tumor infiltrating lymphocytes may be predictive of outcomes after treatment with trastuzumab.

Despite 5-year survival increasing nationally for patients with lung cancer, patients of color continue to experience poor survival.

Patients with intermediate-risk and high-risk renal cell carcinoma had a statistically significant improvement in disease-free survival after being treated with pembrolizumab, which was approved by the FDA.

Patients with melanoma who have asymptomatic brain metastases had long-lasting responses after being treated with first-line nivolumab and ipilimumab.

Investigators noted evident racial and ethnic disparities among patients with high prostate-specific antigen levels who received subsequent prostate MRI imaging.

Eric D. Whitman, MD, discusses the clinical trial program at Atlantic Health System, a large nonprofit health care network in New Jersey, and how partnering with the Translational Genomics Research Institute will help to bring better care to patients with cancer.

Patients who received transoral robotic surgery for human papillomavirus–positive oropharynx squamous cell carcinoma were likely to experience pathologic extra nodal extension and positive margins following surgery.

The Centers for Medicare & Medicaid Service has released an interim final rule on COVID-19 vaccination for health care staff participating in Medicare and Medicaid programs, and the Occupation Safety and Health Administration has released an Emergency Temporary Standard for employers with 100 or more staff members.

Findings from the CheckMate 816 trial indicated that the combination of nivolumab and chemotherapy as neoadjuvant therapy resulted in a significant event-free survival benefit for patients with resectable non–small cell lung cancer.

A notable association has been identified between non-clear cell renal cell carcinoma and proliferative disease.

Patients with cholangiocarcinoma may derive benefit from treatment with TT-00420, which was recently given a fast track designation by the FDA.

A priority review was granted to toripalimab by the FDA for 2 indications in patients with advanced nasopharyngeal carcinoma.

Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced good quality of life and promising survival benefit after being treated with de-escalated adjuvant radiation therapy.

Patients with relapsed or refractory follicular lymphoma who have received 2 prior lines of therapy appear to benefit from treatment with tisagenlecleucel, which was granted a priority review by the FDA.